What is the recommended dosing regimen for tocilizumab?

Tocilizumab Dosing Recommendations

Systemic Autoimmune Rheumatic Disease-Associated Interstitial Lung Disease (SARD-ILD)

For SARD-ILD, administer tocilizumab 162 mg subcutaneously weekly. 1

• Monitor CBC with differential at baseline, 4–8 weeks after starting therapy, and every 3 months thereafter 1
• Check ALT/AST, alkaline phosphatase, and total bilirubin at baseline, every 4–8 weeks for the first 6 months, then every 3 months 1
• Obtain lipid panel at baseline, 4–8 weeks after starting, at 6 months, then annually 1
• Screen for latent tuberculosis before initiation 1

---

Cytokine Release Syndrome (CRS) Following CAR T-Cell Therapy

For grade ≥2 CRS, give tocilizumab 8 mg/kg IV (maximum 800 mg) as the initial dose. 1

Dosing Algorithm by CRS Grade:

• Grade 1 CRS: Consider tocilizumab 8 mg/kg IV (max 800 mg) if symptoms persist >24 hours (for axicabtagene ciloleucel or brexucabtagene autoleucel) or if CRS develops <72 hours after infusion (for lisocabtagene maraleucel) 1

• Grade 2 CRS: Administer tocilizumab 8 mg/kg IV (max 800 mg) immediately 1

  • If no improvement within 3 days, repeat tocilizumab 8 mg/kg IV (max 800 mg) 1
  • Consider adding dexamethasone 10 mg IV every 6–24 hours depending on CAR T product 1

• Grade 3–4 CRS: Give tocilizumab 8 mg/kg IV (max 800 mg) immediately before ICU transfer 1

  • Add dexamethasone 10 mg IV every 6 hours for grade 3 1
  • Escalate to dexamethasone 20 mg IV every 6 hours for grade 4 1
  • Maximum of 1 additional tocilizumab dose if no improvement 1

Pediatric Dosing:

• Children <30 kg: Use tocilizumab 12 mg/kg IV (instead of 8 mg/kg) 1

Conservation Strategy (Limited Supply):

• Limit tocilizumab to maximum 2 doses per CRS episode 1
• Use steroids more aggressively 1
• Consider replacing second dose with siltuximab or anakinra if necessary 1

---

Steroid-Refractory Acute Graft-Versus-Host Disease (aGVHD)

For steroid-refractory aGVHD, administer tocilizumab 8 mg/kg IV every 2–3 weeks (preferably every 2 weeks for optimal response). 1

• Overall response rate ranges from 44–67%, with complete response rates of 22–63% depending on dosing frequency 1
• Patients with skin or GI involvement show the greatest response; liver involvement shows minimal benefit 1
• Monitor closely for infectious complications, particularly bacterial infections 1

---

Juvenile Idiopathic Arthritis (JIA)

Monitor CBC and liver function tests within the first 1–2 months of tocilizumab initiation and every 3–4 months thereafter. 1

• Check lipid levels every 6 months per package insert 1
• Dose adjustments for laboratory abnormalities: 1
  • Elevated LFTs (1–3× ULN): Decrease dose or increase interval between doses
  • Elevated LFTs (>3× ULN): Withhold administration
  • Elevated LFTs (>5× ULN): Discontinue treatment
  • Neutropenia (500–1,000/mm³): Adjust dosing
  • Thrombocytopenia (50,000–100,000/mm³): Adjust dosing

---

Giant Cell Arteritis (GCA)

For GCA, administer tocilizumab 162 mg subcutaneously weekly combined with a 26-week prednisone taper. 2, 3, 4

• Weekly subcutaneous dosing achieves sustained glucocorticoid-free remission in 56% of patients at 52 weeks 4
• Every-other-week dosing (162 mg SC) achieves 53% remission rate 4
• Tocilizumab reduces cumulative prednisone exposure from 3,296–3,818 mg to 1,862 mg over 52 weeks 4
• Continue tocilizumab for 12 months regardless of prednisone duration 2

Alternative IV Dosing:

• Tocilizumab 6 mg/kg IV every 4 weeks may be used, though subcutaneous weekly dosing is preferred 3

---

Rheumatoid Arthritis (RA)

For RA, use tocilizumab 8 mg/kg IV every 4 weeks (in combination with methotrexate) or 162 mg subcutaneously weekly. 1, 5, 6

• Weight-based considerations for subcutaneous dosing: 6
  • Patients ≥100 kg: Use 162 mg SC weekly only (every-2-week dosing results in inadequate exposure and lower efficacy)
  • Patients <100 kg: Either 162 mg SC weekly or every 2 weeks is acceptable
• Tocilizumab monotherapy shows superiority over methotrexate alone, but combination therapy is preferred 1
• Steady-state predose concentrations: 40 μg/mL (SC weekly), 7.4 μg/mL (SC every 2 weeks), 18 μg/mL (IV every 4 weeks) 6

---

COVID-19 (Not Recommended Based on Evidence)

Tocilizumab 8 mg/kg IV (maximum 800 mg) was studied in hospitalized COVID-19 patients but did NOT demonstrate efficacy for preventing intubation or death. 7

• Hazard ratio for intubation or death: 0.83 (95% CI, 0.38–1.81; P=0.64) 7
• No benefit observed for disease worsening or time to discontinuation of supplemental oxygen 7
• Alternative fixed dosing of 600 mg IV has been proposed based on pharmacokinetic modeling to reduce drug waste and costs, though this remains investigational 8

---

Bispecific Antibody-Induced CRS (Anti-CD20 bsAb)

For anti-CD20 bispecific antibody-induced CRS in relapsed/refractory B-cell non-Hodgkin lymphoma, use up to two doses of tocilizumab 8 mg/kg IV at least 8 hours apart per CRS event, with a maximum of three doses in 6 weeks. 9

• This schedule is based on IL-6 receptor occupancy modeling specific to bsAb-induced CRS 9
• Differs from CAR T-cell CRS due to lower IL-6 levels and different clinical symptomatology 9

---

Key Monitoring Parameters Across All Indications

• Latent TB screening before initiation 1
• CBC with differential at baseline and regularly during therapy 1
• Liver function tests at baseline and regularly during therapy 1
• Lipid panel monitoring (frequency varies by indication) 1
• Risk of bowel perforation (particularly in patients with diverticulitis history) 1

---

Critical Pitfalls to Avoid

• Never use tocilizumab for ICANS (immune effector cell-associated neurotoxicity syndrome) following CAR T-cell therapy, as it may worsen neurotoxicity by increasing circulating IL-6 1
• Do not use every-2-week subcutaneous dosing in RA patients >100 kg due to inadequate drug exposure and reduced efficacy 6
• Do not exceed maximum tocilizumab doses in CRS management to avoid unnecessary drug exposure and costs 1